hydroxychloroquine has been researched along with Dermatomyositis in 54 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Dermatomyositis: A subacute or chronic inflammatory disease of muscle and skin, marked by proximal muscle weakness and a characteristic skin rash. The illness occurs with approximately equal frequency in children and adults. The skin lesions usually take the form of a purplish rash (or less often an exfoliative dermatitis) involving the nose, cheeks, forehead, upper trunk, and arms. The disease is associated with a complement mediated intramuscular microangiopathy, leading to loss of capillaries, muscle ischemia, muscle-fiber necrosis, and perifascicular atrophy. The childhood form of this disease tends to evolve into a systemic vasculitis. Dermatomyositis may occur in association with malignant neoplasms. (From Adams et al., Principles of Neurology, 6th ed, pp1405-6)
| Excerpt | Relevance | Reference |
|---|---|---|
| "The population included subjects aged ≥18 years with at least moderately active dermatomyositis skin activity by Cutaneous Dermatomyositis Disease Area and Severity Index activity ≥ 14 and failure or intolerance to hydroxychloroquine." | 9.51 | Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial. ( Bashir, MM; Concha, JSS; Constantine, S; Dgetluck, N; Feng, R; Gebre, K; Haber, J; Hejazi, E; Jadoo, AS; Okawa, J; Pena, SM; Reddy, N; Werth, VP; White, B; Zeidi, M, 2022) |
| "Hydroxychloroquine sulfate is a commonly used medication for patients with dermatomyositis and has been associated with a uniquely elevated risk of adverse cutaneous reactions in this population." | 7.88 | Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis. ( Casciola-Rosen, L; Fiorentino, DF; Wolstencroft, PW, 2018) |
| "We report 3 cases of recalcitrant dermatomyositis that responded to the addition of daily leflunomide, a novel immunomodulatory drug that is currently used to treat rheumatoid arthritis." | 7.74 | Leflunomide as adjuvant treatment of dermatomyositis. ( Boswell, JS; Costner, MI, 2008) |
| "Hydroxychloroquine sulfate and other antimalarial drugs have been used successfully as adjunctive therapy for patients with cutaneous lesions of dermatomyositis over the past 20 years." | 7.71 | Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. ( Callen, JP; Pelle, MT, 2002) |
| "Dapsone therapy for cutaneous dermatomyositis may have a wider role in treatment for these patients refractory to prednisone and antimalarial therapy." | 7.71 | Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. ( Cohen, JB, 2002) |
| "We report one case of dermatomyositis and one case of polymyositis and scleroderma in which the patients' condition improved after treatment with cyclosporine (cyclosporine A)." | 7.68 | Cyclosporine treatment for dermatomyositis/polymyositis. ( Mehregan, DR; Su, WP, 1993) |
| "We examined retrospectively the use of hydroxychloroquine in 9 patients with childhood dermatomyositis (DM)." | 7.67 | Adjunctive use of hydroxychloroquine in childhood dermatomyositis. ( Lindsley, CB; Olson, NY, 1989) |
| "The population included subjects aged ≥18 years with at least moderately active dermatomyositis skin activity by Cutaneous Dermatomyositis Disease Area and Severity Index activity ≥ 14 and failure or intolerance to hydroxychloroquine." | 5.51 | Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial. ( Bashir, MM; Concha, JSS; Constantine, S; Dgetluck, N; Feng, R; Gebre, K; Haber, J; Hejazi, E; Jadoo, AS; Okawa, J; Pena, SM; Reddy, N; Werth, VP; White, B; Zeidi, M, 2022) |
| "Antimalarials are used to treat dermatomyositis (DM) and cutaneous lupus erythematosus (CLE)." | 5.46 | Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus. ( Alves, P; Bashir, MM; Feng, R; Werth, VP; Wysocka, M; Zeidi, M, 2017) |
| " In two patients the corticosteroid dosage could be tapered." | 5.27 | Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. ( Bickers, DR; Callen, JP; Hanno, R; Hawkins, C; Voorhees, JJ; Woo, TY, 1984) |
| " We present a 52-year-old woman with a history of amyopathic dermatomyositis complicated by interstitial lung disease managed with mycophenolate mofetil and hydroxychloroquine who presented with a 7-month history of recurrent subcutaneous nodules as well as intermittent diarrhea and chronic sinusitis." | 3.96 | Cutaneous microsporidiosis in an immunosuppressed patient. ( Bradt, AR; Fullen, DR; Goldsmith, CS; Nadelman, DA; Qvarnstrom, Y; Smith, EH; Wang, F; Zaki, SR, 2020) |
| "Hydroxychloroquine sulfate is a commonly used medication for patients with dermatomyositis and has been associated with a uniquely elevated risk of adverse cutaneous reactions in this population." | 3.88 | Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis. ( Casciola-Rosen, L; Fiorentino, DF; Wolstencroft, PW, 2018) |
| "We report 3 cases of recalcitrant dermatomyositis that responded to the addition of daily leflunomide, a novel immunomodulatory drug that is currently used to treat rheumatoid arthritis." | 3.74 | Leflunomide as adjuvant treatment of dermatomyositis. ( Boswell, JS; Costner, MI, 2008) |
| "Hydroxychloroquine sulfate and other antimalarial drugs have been used successfully as adjunctive therapy for patients with cutaneous lesions of dermatomyositis over the past 20 years." | 3.71 | Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. ( Callen, JP; Pelle, MT, 2002) |
| "Dapsone therapy for cutaneous dermatomyositis may have a wider role in treatment for these patients refractory to prednisone and antimalarial therapy." | 3.71 | Cutaneous involvement of dermatomyositis can respond to Dapsone therapy. ( Cohen, JB, 2002) |
| "We report one case of dermatomyositis and one case of polymyositis and scleroderma in which the patients' condition improved after treatment with cyclosporine (cyclosporine A)." | 3.68 | Cyclosporine treatment for dermatomyositis/polymyositis. ( Mehregan, DR; Su, WP, 1993) |
| "We examined retrospectively the use of hydroxychloroquine in 9 patients with childhood dermatomyositis (DM)." | 3.67 | Adjunctive use of hydroxychloroquine in childhood dermatomyositis. ( Lindsley, CB; Olson, NY, 1989) |
| "Treatment with prednisone and hydroxychloroquine led to complete control of the cutaneous and muscular involvement, which was maintained during prednisone tapering." | 2.42 | Inflammatory myopathy in a patient with cutaneous findings of pityriasis rubra pilaris: a case of Wong's dermatomyositis. ( Bellosta, M; Bogliolo, L; Caporali, R; Cavagna, L; Montecucco, C, 2004) |
| "Dermatomyositis is an idiopathic inflammatory myopathy with characteristic skin manifestations." | 2.41 | Dermatomyositis. ( Koler, RA; Montemarano, A, 2001) |
| "In patients with severe or refractory juvenile dermatomyositis (DM), second-line treatments may be required." | 1.48 | Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling. ( Campanilho-Marques, R; Deakin, CT; Moraitis, E; Pilkington, CA; Pullenayegum, E; Simou, S; Wedderburn, LR, 2018) |
| "Antimalarials are used to treat dermatomyositis (DM) and cutaneous lupus erythematosus (CLE)." | 1.46 | Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus. ( Alves, P; Bashir, MM; Feng, R; Werth, VP; Wysocka, M; Zeidi, M, 2017) |
| "Hydroxychloroquine (HCQ) has a low risk of retinal toxicity which increases dramatically with a cumulative dose of >1000 g." | 1.43 | A possible early sign of hydroxychloroquine macular toxicity. ( Brandao, LM; Palmowski-Wolfe, AM, 2016) |
| "Pruritus was the most common initial symptom reported in both groups, while periungual erythema and Gottron's papules were the most common skin presentations." | 1.39 | A comparative study of clinical characteristics, work-up, treatment, and association to malignancy in dermatomyositis between two tertiary skin centers in the USA and Singapore. ( Carroll, C; Chan, YH; Jorizzo, J; Kannagra, A; LoSicco, K; Manabat, CG; Ng, P; Tan, A; Yosipovitch, G, 2013) |
| "While dermatomyositis affects thousands of individuals in the United States, laryngeal involvement has only been described in a single case report to date." | 1.39 | Dysphonia and dermatomyositis: an unusual manifestation. ( McNeill, E; Mims, JW; Wood, MW; Wright, SC, 2013) |
| "Lipodystrophy was seen in 10/33 (30." | 1.33 | Twelve years experience of juvenile dermatomyositis in North India. ( Bansal, A; Singh, S, 2006) |
| "She was diagnosed as having lupus panniculitis." | 1.32 | Lupus panniculitis with combined features of dermatomyositis resulting in severe lipoatrophy. ( Cho, KH; Jo, SJ; Yoo, JY, 2004) |
| "The histopathology revealed septal panniculitis, and the nodules have been under regression." | 1.30 | Methotrexate nodulosis. ( Choi, JH; Jang, KA; Koh, JK; Moon, KC; Sung, KJ; Yoo, B, 1999) |
| "However, DM without muscle weakness is a clinical entity with respect to favorable long-term prognosis." | 1.29 | Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids. ( Amaudric, F; Cosnes, A; Gherardi, R; Revuz, J; Roujeau, JC; Verroust, J; Wechsler, J, 1995) |
| " In two patients the corticosteroid dosage could be tapered." | 1.27 | Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine. ( Bickers, DR; Callen, JP; Hanno, R; Hawkins, C; Voorhees, JJ; Woo, TY, 1984) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 6 (11.11) | 18.7374 |
| 1990's | 7 (12.96) | 18.2507 |
| 2000's | 18 (33.33) | 29.6817 |
| 2010's | 18 (33.33) | 24.3611 |
| 2020's | 5 (9.26) | 2.80 |
| Authors | Studies |
|---|---|
| Werth, VP | 6 |
| Hejazi, E | 1 |
| Pena, SM | 1 |
| Haber, J | 1 |
| Zeidi, M | 4 |
| Reddy, N | 1 |
| Okawa, J | 1 |
| Feng, R | 3 |
| Bashir, MM | 3 |
| Gebre, K | 1 |
| Jadoo, AS | 1 |
| Concha, JSS | 1 |
| Dgetluck, N | 1 |
| Constantine, S | 1 |
| White, B | 2 |
| Nadelman, DA | 1 |
| Bradt, AR | 1 |
| Qvarnstrom, Y | 1 |
| Goldsmith, CS | 1 |
| Zaki, SR | 1 |
| Wang, F | 1 |
| Smith, EH | 1 |
| Fullen, DR | 1 |
| Quintana-Ortega, C | 1 |
| Remesal, A | 1 |
| Ruiz de Valbuena, M | 1 |
| de la Serna, O | 1 |
| Laplaza-González, M | 1 |
| Álvarez-Rojas, E | 1 |
| Udaondo, C | 1 |
| Alcobendas, R | 1 |
| Murias, S | 1 |
| Akabane, AL | 1 |
| Smith, GP | 1 |
| Chen, KL | 1 |
| Patel, J | 1 |
| Wysocka, M | 2 |
| Patel, B | 1 |
| Maddukuri, S | 1 |
| Alves, P | 1 |
| Mittal, L | 1 |
| Zhang, L | 1 |
| Deakin, CT | 1 |
| Campanilho-Marques, R | 1 |
| Simou, S | 1 |
| Moraitis, E | 1 |
| Wedderburn, LR | 1 |
| Pullenayegum, E | 1 |
| Pilkington, CA | 1 |
| Koroscil, MT | 1 |
| Rohan, CA | 1 |
| Morris, MJ | 1 |
| Scott, JN | 1 |
| Tidwell, WJ | 1 |
| Callen, JP | 3 |
| Wolstencroft, PW | 1 |
| Casciola-Rosen, L | 1 |
| Fiorentino, DF | 1 |
| Chansky, PB | 1 |
| Gaffney, RG | 1 |
| Gonzalez, CD | 1 |
| Hansen, C | 1 |
| Clarke, JT | 2 |
| Femia, AN | 1 |
| Eastham, AB | 1 |
| Lam, C | 1 |
| Merola, JF | 1 |
| Qureshi, AA | 1 |
| Vleugels, RA | 2 |
| Canavan, T | 1 |
| Sidorsky, T | 1 |
| Doan, LT | 1 |
| Ricardo-Gonzalez, RR | 1 |
| Shen, G | 1 |
| Rosenblum, MD | 1 |
| Brandao, LM | 1 |
| Palmowski-Wolfe, AM | 1 |
| Kurtzman, DJ | 1 |
| Ho, A | 1 |
| Wright, NA | 1 |
| Rubenstein, MH | 1 |
| Kavala, M | 1 |
| Sudogan, S | 1 |
| Can, B | 1 |
| Zindanci, I | 1 |
| Kuru, I | 1 |
| Beyhan, S | 1 |
| Kocaturk, E | 1 |
| Laswad, T | 1 |
| Alamo, L | 1 |
| Hofer, M | 1 |
| Rotman, S | 1 |
| Gudinchet, F | 1 |
| Inhoff, O | 1 |
| Peitsch, WK | 1 |
| Paredes, BE | 1 |
| Goerdt, S | 1 |
| Goebeler, M | 1 |
| Boente, Mdel C | 1 |
| Nadra, G | 1 |
| Asial, R | 1 |
| Happle, R | 1 |
| Lieberman, SM | 1 |
| Sherry, DD | 1 |
| Iba-Ba, J | 1 |
| Mayi-Tsonga, S | 1 |
| Ibouili Bignoumba, R | 1 |
| Diallo, T | 1 |
| Moussavou Kombila, JB | 1 |
| Coniquet, S | 1 |
| Mihindou Boussougou, C | 1 |
| Boguikouma, JB | 1 |
| Teh, CL | 1 |
| Wong, JS | 1 |
| Soo, HH | 1 |
| Yosipovitch, G | 1 |
| Tan, A | 1 |
| LoSicco, K | 1 |
| Manabat, CG | 1 |
| Kannagra, A | 1 |
| Carroll, C | 1 |
| Chan, YH | 1 |
| Ng, P | 1 |
| Jorizzo, J | 1 |
| Foulke, G | 1 |
| Baccon, J | 1 |
| Marks, JG | 1 |
| Wood, MW | 1 |
| McNeill, E | 1 |
| Mims, JW | 1 |
| Wright, SC | 1 |
| Haro, R | 1 |
| Revelles, JM | 1 |
| Fariña, Mdel C | 1 |
| Martín, L | 1 |
| Requena, L | 1 |
| Pelle, MT | 1 |
| RUGGIERO, HA | 1 |
| Caporali, R | 1 |
| Cavagna, L | 1 |
| Bellosta, M | 1 |
| Bogliolo, L | 1 |
| Montecucco, C | 1 |
| Yoo, JY | 1 |
| Jo, SJ | 1 |
| Cho, KH | 1 |
| Singh, S | 1 |
| Bansal, A | 1 |
| Leung, YY | 1 |
| Choi, KW | 1 |
| Ho, KM | 1 |
| Kun, EW | 1 |
| Dold, S | 1 |
| Justiniano, ME | 1 |
| Marquez, J | 1 |
| Espinoza, LR | 1 |
| Aslanidis, S | 1 |
| Pyrpasopoulou, A | 1 |
| Kartali, N | 1 |
| Zamboulis, C | 1 |
| Tweezer-Zaks, N | 1 |
| Ben-Horin, S | 1 |
| Schiby, G | 1 |
| Bank, I | 1 |
| Levi, Y | 1 |
| Livneh, A | 1 |
| Langevitz, P | 1 |
| Arnson, Y | 1 |
| Dovrish, Z | 1 |
| Hadari, R | 1 |
| Amital, H | 1 |
| Boswell, JS | 1 |
| Costner, MI | 1 |
| Woo, TY | 1 |
| Voorhees, JJ | 1 |
| Bickers, DR | 1 |
| Hanno, R | 1 |
| Hawkins, C | 1 |
| Cosnes, A | 1 |
| Amaudric, F | 1 |
| Gherardi, R | 1 |
| Verroust, J | 1 |
| Wechsler, J | 1 |
| Revuz, J | 1 |
| Roujeau, JC | 1 |
| Cox, NH | 1 |
| Bloom, BJ | 1 |
| Tucker, LB | 1 |
| Klein-Gitelman, M | 1 |
| Miller, LC | 1 |
| Schaller, JG | 2 |
| King, LE | 1 |
| Park, JH | 1 |
| Adams, LB | 1 |
| Olsen, NJ | 1 |
| Mehregan, DR | 1 |
| Su, WP | 1 |
| Jang, KA | 1 |
| Choi, JH | 1 |
| Moon, KC | 1 |
| Yoo, B | 1 |
| Sung, KJ | 1 |
| Koh, JK | 1 |
| Koler, RA | 1 |
| Montemarano, A | 1 |
| Cohen, JB | 1 |
| Olson, NY | 1 |
| Lindsley, CB | 1 |
| Belaïch, S | 1 |
| Crickx, B | 1 |
| Picard, C | 1 |
| Lazareth, I | 1 |
| Fegueux, S | 1 |
| Barthélémy, H | 1 |
| Bilbault, P | 1 |
| James, WD | 1 |
| Dawson, N | 1 |
| Rodman, OG | 1 |
| Henkind, P | 1 |
| Gold, DH | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2, Double-blind, Randomized, Placebo-controlled Study to Investigate the Safety, Tolerability, and Efficacy of JBT-101 in Subjects With Dermatomyositis[NCT02466243] | Phase 2 | 22 participants (Actual) | Interventional | 2015-06-30 | Terminated (stopped due to Sponsor terminated open-label extension.) | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
The CDASI is a validated outcome measure that systematically quantifies cutaneous DM disease activity, In the CDASI, DM skin disease activity is scored from 0 to 100 based on the physician's evaluation of erythema, scale, and erosion or ulceration at 15 anatomic locations as well as alopecia, Gottron's sign or papules on the hands, and periungual changes. A 5-point or greater decrease in the CDASI activity score indicates clinically relevant improvement based on statistical analysis using a receiver operating characteristic curve to maximize sensitivity and specificity (NCT02466243)
Timeframe: Part A: 84-day treatment period (Change from the Baseline CDSAI score at Day 84)
| Intervention | CDASI Activity Score (Least Squares Mean) |
|---|---|
| Lenabasum | -8.0 |
| Placebo | -5.5 |
"LS mean (SE) change from baseline to Week 6 (Day 84) for lenabasum vs. placebo using a mixed model repeated measures analysis~The CDASI is a validated outcome measure that systematically quantifies cutaneous DM disease activity and damage, In the CDASI, the Damage Score is scored from 0 to 32 based on the physician's evaluation of poikiloderma and calcinosis. 0 representing no damage and 32 representing the greatest level of damage." (NCT02466243)
Timeframe: Part A: 84-day treatment period
| Intervention | CDASI Damage Score (Least Squares Mean) |
|---|---|
| Placebo | -5.5 |
| Lenabasum 20 mg BID | -8.0 |
6 reviews available for hydroxychloroquine and Dermatomyositis
| Article | Year |
|---|---|
An extremely severe case of cutaneous calcinosis complicating adult dermatomyositis.
Topics: Adult; Antirheumatic Agents; Azathioprine; Calcinosis; Dermatomyositis; Drug Therapy, Combination; F | 2009 |
[Tumoral calcinosis in a child: a case report and review].
Topics: Antirheumatic Agents; Calcinosis; Child; Dermatomyositis; Elbow Joint; Female; Follow-Up Studies; Hu | 2009 |
Wong's dermatomyositis: a new case and review of the literature.
Topics: Antirheumatic Agents; Dermatomyositis; Female; Humans; Hydroxychloroquine; Middle Aged; Muscle Weakn | 2013 |
Inflammatory myopathy in a patient with cutaneous findings of pityriasis rubra pilaris: a case of Wong's dermatomyositis.
Topics: Anti-Inflammatory Agents; Dermatologic Agents; Dermatomyositis; Drug Therapy, Combination; Female; H | 2004 |
Dermatomyositis.
Topics: Adult; Azathioprine; Child; Dermatologic Agents; Dermatomyositis; Diagnosis, Differential; Female; H | 2001 |
Ocular manifestations of rheumatic disorders. Natural and iatrogenic.
Topics: Adrenal Cortex Hormones; Arteritis; Arthritis, Juvenile; Arthritis, Rheumatoid; Chloroquine; Conjunc | 1973 |
1 trial available for hydroxychloroquine and Dermatomyositis
| Article | Year |
|---|---|
Safety and Efficacy of Lenabasum, a Cannabinoid Receptor Type 2 Agonist, in Patients with Dermatomyositis with Refractory Skin Disease: A Randomized Clinical Trial.
Topics: Adolescent; Adult; Biomarkers; Cannabinoid Receptor Agonists; Dermatomyositis; Double-Blind Method; | 2022 |
47 other studies available for hydroxychloroquine and Dermatomyositis
| Article | Year |
|---|---|
Cutaneous microsporidiosis in an immunosuppressed patient.
Topics: Dermatomycoses; Dermatomyositis; Enzyme Inhibitors; Female; Humans; Hydroxychloroquine; Immunocompro | 2020 |
Fatal outcome of anti-MDA5 juvenile dermatomyositis in a paediatric COVID-19 patient: a case report.
Topics: Adenosine Monophosphate; Alanine; Anti-Bacterial Agents; Antibodies, Monoclonal, Humanized; Antivira | 2021 |
Adverse cutaneous reactions secondary to hydroxychloroquine in patients with dermatomyositis, lupus erythematosus, and lichen planopilaris.
Topics: Dermatomyositis; Humans; Hydroxychloroquine; Lichen Planus; Lupus Erythematosus, Cutaneous; Lupus Er | 2021 |
Myeloid Dendritic Cells Are Major Producers of IFN-β in Dermatomyositis and May Contribute to Hydroxychloroquine Refractoriness.
Topics: Aged; Biopsy; Dendritic Cells; Dermatomyositis; Female; Humans; Hydroxychloroquine; Immunohistochemi | 2021 |
Quinacrine Suppresses Tumor Necrosis Factor-α and IFN-α in Dermatomyositis and Cutaneous Lupus Erythematosus.
Topics: Antimalarials; Cells, Cultured; Dendritic Cells; Dermatomyositis; Drug Interactions; Humans; Hydroxy | 2017 |
Antimalarial drug toxicities in patients with cutaneous lupus and dermatomyositis: A retrospective cohort study.
Topics: Adult; Age Factors; Antimalarials; Chloroquine; Cohort Studies; Databases, Factual; Dermatomyositis; | 2018 |
Efficacy and Safety of Cyclophosphamide Treatment in Severe Juvenile Dermatomyositis Shown by Marginal Structural Modeling.
Topics: Antirheumatic Agents; Azathioprine; Child; Child, Preschool; Cohort Studies; Cyclophosphamide; Derma | 2018 |
Wong-Type Dermatomyositis Complicated by Interstitial Lung Disease.
Topics: Adult; Anti-Inflammatory Agents; Antirheumatic Agents; Biopsy; Dermatomyositis; Diagnosis, Different | 2018 |
Koebner Phenomenon in Juvenile Dermatomyositis.
Topics: Adolescent; Anti-Inflammatory Agents; Antirheumatic Agents; Biopsy; Creatine Kinase; Dermatologic Ag | 2018 |
Association Between Autoantibody Phenotype and Cutaneous Adverse Reactions to Hydroxychloroquine in Dermatomyositis.
Topics: Adult; Antirheumatic Agents; Autoantibodies; Dermatomyositis; Drug Eruptions; Female; Humans; Hydrox | 2018 |
Acute onset/flares of dermatomyositis following ingestion of IsaLean herbal supplement: Clinical and immunostimulatory findings.
Topics: Acute Disease; Autoantibodies; Autoimmune Diseases; Dermatomyositis; Dietary Supplements; Humans; Hy | 2019 |
Evaluating results of an interferon-γ release assay in patients with autoimmune disease who are taking hydroxychloroquine.
Topics: Adult; Aged; Anti-Inflammatory Agents; Antirheumatic Agents; Dermatomyositis; Female; Humans; Hydrox | 2019 |
Adverse cutaneous drug reactions with antimalarials in cutaneous lupus and dermatomyositis: A retrospective cohort study.
Topics: Adult; Aged; Aged, 80 and over; Antimalarials; Dermatomyositis; Drug Eruptions; Female; Follow-Up St | 2019 |
Intravenous immunoglobulin for refractory cutaneous dermatomyositis: a retrospective analysis from an academic medical center.
Topics: Academic Medical Centers; Adult; Aged; Aged, 80 and over; Cohort Studies; Dermatomyositis; Dose-Resp | 2013 |
A case of Wong-type dermatomyositis with concomitant anti-MDA5 features.
Topics: Biomarkers; Biopsy, Needle; DEAD-box RNA Helicases; Dermatomyositis; Drug Therapy, Combination; Elec | 2014 |
A possible early sign of hydroxychloroquine macular toxicity.
Topics: Adolescent; Antirheumatic Agents; Dermatomyositis; Electroretinography; Female; Humans; Hydroxychlor | 2016 |
Unilateral Gottron Papules in a Patient Following a Stroke: Clinical Insights Into the Disease Mechanisms and Pathophysiology of Cutaneous Dermatomyositis.
Topics: Biopsy, Needle; Dermatomyositis; Drug Therapy, Combination; Female; Hand Dermatoses; Humans; Hydroxy | 2016 |
Simvastatin-induced amyopathic dermatomyositis.
Topics: Aged; Biopsy; Dermatomyositis; Female; Humans; Hydroxychloroquine; Hydroxymethylglutaryl-CoA Reducta | 2009 |
Pronounced linear calcinosis in a boy with mild dermatomyositis. A further possible example of superimposed segmental manifestation of a polygenic disorder.
Topics: Biopsy, Needle; Calcinosis; Child; Colchicine; Dermatomyositis; Disease Progression; Drug Therapy, C | 2009 |
Development of classic dermatomyositis rash years after diagnosis of juvenile polymyositis.
Topics: Anti-Inflammatory Agents; Child; Dermatomyositis; Disease Progression; Drug Therapy, Combination; Ex | 2009 |
[Dermatomyositis and pregnancy: a case in Gabon].
Topics: Adult; Antirheumatic Agents; Cesarean Section; Dermatomyositis; Female; Gabon; Glucocorticoids; Huma | 2009 |
Polymyositis and dermatomyositis in Sarawak: a profile of patients treated in the Sarawak General Hospital.
Topics: Aged; Antirheumatic Agents; Biopsy; Cross-Sectional Studies; Dermatomyositis; Electromyography; Fema | 2012 |
A comparative study of clinical characteristics, work-up, treatment, and association to malignancy in dermatomyositis between two tertiary skin centers in the USA and Singapore.
Topics: Adrenal Cortex Hormones; Adult; Aged; Antibodies, Monoclonal, Murine-Derived; Asian People; Bone Den | 2013 |
Antimalarial myopathy in amyopathic dermatomyositis.
Topics: Aged; Antimalarials; Dermatomyositis; Female; Humans; Hydroxychloroquine; Muscular Diseases | 2012 |
Dysphonia and dermatomyositis: an unusual manifestation.
Topics: Adult; Antirheumatic Agents; Biopsy; Dermatomyositis; Diagnosis, Differential; Drug Therapy, Combina | 2013 |
Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus.
Topics: Adolescent; Adult; Age Distribution; Aged; Aged, 80 and over; Case-Control Studies; Chemotherapy, Ad | 2002 |
[TREATMENT OF COLLAGEN DISEASES].
Topics: Arthritis; Arthritis, Rheumatoid; Autoimmune Diseases; Chloroquine; Collagen Diseases; Dermatomyosit | 1963 |
Lupus panniculitis with combined features of dermatomyositis resulting in severe lipoatrophy.
Topics: Biopsy, Needle; Child; Dermatomyositis; Female; Follow-Up Studies; Humans; Hydroxychloroquine; Immun | 2004 |
Twelve years experience of juvenile dermatomyositis in North India.
Topics: Adolescent; Age of Onset; Azathioprine; Calcinosis; Child; Child, Preschool; Deglutition Disorders; | 2006 |
Disseminated cutaneous infection with Mycobacterium chelonae mimicking panniculitis in a patient with dermatomyositis.
Topics: Antineoplastic Agents, Hormonal; Dermatologic Agents; Dermatomyositis; Diagnosis, Differential; Fema | 2005 |
Treatment of early and refractory dermatomyositis with infliximab: a report of two cases.
Topics: Adult; Antibodies, Monoclonal; Dermatologic Agents; Dermatomyositis; Drug Resistance; Drug Therapy, | 2007 |
Successful treatment of refractory rash in paraneoplastic amyopathic dermatomyositis.
Topics: Adult; Dermatomyositis; Drug Therapy, Combination; Exanthema; Female; Glucocorticoids; Humans; Hydro | 2007 |
Severe gastrointestinal inflammation in adult dermatomyositis: characterization of a novel clinical association.
Topics: Adult; Anti-Inflammatory Agents; Azathioprine; Cyclophosphamide; Dermatomyositis; Fatal Outcome; Fem | 2006 |
Amyopathic dermatomyositis--an uncommon presentation of dermatomyositis.
Topics: Adult; Arthralgia; Cyclosporine; Dermatologic Agents; Dermatomyositis; Exanthema; Glucocorticoids; H | 2007 |
Leflunomide as adjuvant treatment of dermatomyositis.
Topics: Adjuvants, Immunologic; Adult; Aged; Dermatologic Agents; Dermatomyositis; Dose-Response Relationshi | 2008 |
Cutaneous lesions of dermatomyositis are improved by hydroxychloroquine.
Topics: Adenocarcinoma; Adolescent; Adult; Azathioprine; Dermatomyositis; Drug Therapy, Combination; Female; | 1984 |
Dermatomyositis without muscle weakness. Long-term follow-up of 12 patients without systemic corticosteroids.
Topics: Adolescent; Adrenal Cortex Hormones; Adult; Aged; Antirheumatic Agents; Case-Control Studies; Child; | 1995 |
Amyopathic dermatomyositis, photosensitivity and hydroxychloroquine.
Topics: Aged; Aged, 80 and over; Dermatomyositis; Female; Humans; Hydroxychloroquine; Light | 1995 |
Worsening of the rash of juvenile dermatomyositis with hydroxychloroquine therapy.
Topics: Child; Dermatomyositis; Female; Humans; Hydroxychloroquine | 1994 |
Phosphorus 31 magnetic resonance spectroscopy for quantitative evaluation of therapeutic regimens in dermatomyositis.
Topics: Adenosine Triphosphate; Adult; Azathioprine; Dermatomyositis; Evaluation Studies as Topic; Female; F | 1995 |
Cyclosporine treatment for dermatomyositis/polymyositis.
Topics: Azathioprine; Cyclosporine; Dermatomyositis; Female; Humans; Hydroxychloroquine; Middle Aged; Polymy | 1993 |
Therapy for childhood rheumatic diseases. Have we been doing enough?
Topics: Administration, Oral; Anti-Inflammatory Agents, Non-Steroidal; Arthritis, Juvenile; Child; Child, Pr | 1993 |
Methotrexate nodulosis.
Topics: Arm; Biopsy; Dermatologic Agents; Dermatomyositis; Female; Histocytochemistry; Humans; Hydroxychloro | 1999 |
Cutaneous involvement of dermatomyositis can respond to Dapsone therapy.
Topics: Adult; Aged; Aged, 80 and over; Anti-Infective Agents; Dapsone; Dermatomyositis; Diagnosis, Differen | 2002 |
Adjunctive use of hydroxychloroquine in childhood dermatomyositis.
Topics: Adolescent; Antineoplastic Agents; Child; Dermatomyositis; Drug Therapy, Combination; Female; Humans | 1989 |
[Porphyria cutanea tarda associated with pure cutaneous dermatomyositis].
Topics: Dermatomyositis; Hand Dermatoses; Humans; Hydroxychloroquine; Male; Middle Aged; Porphyrias; Skin Di | 1989 |
The treatment of dermatomyositis with hydroxchloroquine.
Topics: Dermatomyositis; Humans; Hydroxychloroquine; Male; Middle Aged | 1985 |